Skip to main content
. Author manuscript; available in PMC: 2019 Jul 7.
Published in final edited form as: Mucosal Immunol. 2019 Jan 7;12(2):445–456. doi: 10.1038/s41385-018-0117-1

Figure 4. α-SCF248 attenuates chronic pulmonary disease in mouse model.

Figure 4.

Chronic allergen challenged animals were treated by systemic administration of the α-SCF248 during the last four allergen challenges and attenuated disease severity was observed as indicated by A) Lung histologic examinations PAS stain for mucus detection, shows decreased mucus deposition in the mice treated with α-SCF248 compare with IgG. B) qPCR of mucus-related gene Gob5. C) Flow cytometry assessed lung Mast cells, Eosinophils and ILC2. D) Flow cytometry T cells. E) Airway hyperactivity AHR. F) Serum extracellular domain of SCF measured by ELISA was reduced in the anti-SCF248 treated animals. G) qPCR of lung cytokine IL-13 expression demonstrated decreased allergic inflammation. H) IL-13 expression in Sorted ILC2 and CD4+ cells from allergic mice, and I) Gata 3 expression relative to GAPDH control gene expression. Together these data reflect the importance of the isoform SCF248 for the progression of chronic allergic disease. Data represent mean ± SE, from 4-5 mice/group. All data are representative of two to three independent experiments. *P<0.05, **P<0.01, ***P<0.001